Recent Company News

• 04:26 AM ET Apr 30, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:17 PM ET Apr 29, 2025
  

  Abivax completes enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis (€6.25, 0.00)

• 10:25 AM ET Apr 09, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (697 total)

• 10:18 AM ET Apr 07, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1167 total)

• 05:55 AM ET Apr 04, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (337 total)

• 03:35 AM ET Mar 24, 2025
  

  Abivax reports FY net income (€176.2M) vs FactSet (€172.6M) [6 est, (€194.0)-(151.9M)] (€6.79, 0.00)

• 04:19 PM ET Mar 20, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:41 AM ET Mar 20, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:24 AM ET Mar 20, 2025
  

  Morgan Stanley initiates CLDX; assumes ABVX, BPMC